Holen Sie sich die Stockscreener-App
39.04
0.99%
-0.39
Handel nachbörslich:
39.04
Schlusskurs vom Vortag:
$39.43
Offen:
$39.9
24-Stunden-Volumen:
2.48M
Relative Volume:
1.25
Marktkapitalisierung:
$4.61B
Einnahmen:
$1.29B
Nettoeinkommen (Verlust:
$251.00M
KGV:
19.77
EPS:
1.9744
Netto-Cashflow:
$-193.86M
1W Leistung:
+0.80%
1M Leistung:
-3.70%
6M Leistung:
+13.36%
1J Leistung:
+66.27%
1-Tages-Spanne:
$38.73
$40.00
1-Wochen-Bereich:
$37.82
$40.00
52-Wochen-Spanne:
$22.22
$42.81
Indivior Pharmaceuticals Inc Stock (INDV) Company Profile
Firmenname
Indivior Pharmaceuticals Inc
Sektor
Telefon
804-379-1090
Adresse
10710 MIDLOTHIAN TURNPIKE, NORTH CHESTERFIELD
Compare INDV vs TAK, TEVA, HLN, ZTS, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
INDV
Indivior Pharmaceuticals Inc
|
39.04 | 4.65B | 1.29B | 251.00M | -193.86M | 1.9744 |
TAK
Takeda Pharmaceutical Co Adr
|
18.34 | 57.64B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
37.47 | 42.63B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.87 | 42.75B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
76.68 | 30.56B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
529.14 | 22.23B | 3.17B | 1.29B | 1.01B | 27.09 |
Indivior Pharmaceuticals Inc Stock (INDV) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-06 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-07-22 | Fortgesetzt | Jefferies | Buy |
| 2025-01-28 | Eingeleitet | Rodman & Renshaw | Buy |
| 2024-07-23 | Eingeleitet | Piper Sandler | Overweight |
| 2024-04-03 | Eingeleitet | Craig Hallum | Buy |
| 2023-07-13 | Eingeleitet | Northland Capital | Outperform |
Alle ansehen
Indivior Pharmaceuticals Inc Aktie (INDV) Neueste Nachrichten
Indivior stock edges higher as options activity and analyst targets point to further upside - Ad-hoc-news.de
Indivior Q2 2026 Earnings Call: Complete Transcript - Sahm
Indivior Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:INDV - TradingView
Is Indivior Pharmaceuticals (INDV) Below Fair Value Despite A 194% Return? - Sahm
Indivior Pharmaceuticals, Inc. Revenue Breakdown – FWB:E7P - TradingView
Oaktree trims Indivior (INDV) holdings, files Schedule 13D exit amendment - Stock Titan
Indivior Pharmaceuticals, Inc. (INDV) Options Chain - Yahoo! Finance Canada
Morgan Lewis Advises Supernus Pharmaceuticals on Merger with Indivior Pharmaceuticals – News - Morgan Lewis
Layoff Tracker: MindMaze trims Relief staff, Aardvark cuts workforce amid Prader-Willi troubles - BioSpace
Indivior Pharmaceuticals, Inc. (INDV) Stock Forecasts - Yahoo Finance
Indivior Plc (INDV) News, Articles, Events & Latest Updates - Stocktwits
Indivior Pharmaceuticals (INDV) Agrees Merger That Creates New Supernus, Inc. - simplywall.st
Indivior Pharmaceuticals, Inc. (INDV) stock price, news, quote and history - uk.finance.yahoo.com
Is Indivior Pharmaceuticals Inc. (INDV) a Solid Growth Stock? 3 Reasons to Think "Yes" - Yahoo Finance
Indivior Pharmaceuticals, Inc. (INDV) Stock Analysis: Exploring a 27% Potential Upside Amid Strong Revenue Growth - DirectorsTalk Interviews
Hennion & Walsh Asset Management Inc. Invests $14.78 Million in Indivior PLC $INDV - MarketBeat
Assenagon Asset Management S.A. Buys Shares of 1,540,928 Indivior PLC $INDV - MarketBeat
Supernus Pharmaceuticals, Inc. (SUPN) Indivior Pharmaceuticals, Inc.,M&A CallSlideshow - Seeking Alpha
Are BOW, ATKR, SUPN Obtaining Fair Deals for their Shareholders? - tradingview.com
Rockville-Based Supernus and Indivior Agree to Merge, Creating a $2.2B CNS Powerhouse Headquartered in Maryland - BioBuzz
Indivior Pharmaceuticals Inc (INDV) Shares Surge 6.1% -- What GF Score of 75 Tells Investors - GuruFocus
Indivior Pharmaceuticals (INDV) CAO purchases 1,500 common shares - Stock Titan
Supernus And Indivior To Merge And Create $2.2 Billion CNS Biopharmaceutical Company - pulse2.com
Earnings call transcript: Supernus jumps on Indivior merger in Q2 2026 - Investing.com Nigeria
Supernus Pharmaceuticals Falls as Investors Weigh Newly Announced Indivior Merger Terms - moomoo.com
Supernus Pharmaceuticals falls as investors weigh newly announced Indivior merger terms - Quiver Quantitative
Supernus and Indivior to Merge, Creating Diversified CNS Biopharma Company - Contract Pharma
$1.8bn merger unites Supernus and Indivior in CNS therapeutics play - BioXconomy
INDV to Merge With Supernus, Beats on Q2 Earnings, Raises '26 Outlook - Yahoo Finance
Indivior Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Supernus and Indivior merge to create scaled, CNS-focused entity - Yahoo Finance
Raleigh drug factory part of $2B merger - The Business Journals
Indivior Pharmaceuticals, Inc. (INDV) Stock Analysis: Analyst Consensus Points to 36% Upside Potential - DirectorsTalk Interviews
Supernus, Indivior merge to strengthen neuroscience drug portfolio - 1470 & 100.3 WMBD
Indivior and Supernus (SUPN) outline tax-free all-stock CNS merger of equals - stocktitan.net
Supernus and Indivior to merge, forming $2.2B CNS drug company - Dealroom
Supernus Pharmaceuticals (SUPN) outlines investor and employee outreach on Indivior merger of equals - Stock Titan
Indivior Pharmaceuticals, Inc. 2026: Revenue $343M, EPS $0.98— 10-Q Summary - TradingView
Supernus and Indivior to Merge, Forming a New CNS-Focused Pharma Company - MedCity News
Indivior Falls as Investors Reposition Ahead of Second-Quarter Results - Quiver Quantitative
Supernus to Combine with Indivior To Form CNS Biopharmaceutical Leader with Potential $2 Billion in Revenue - Benzinga
Indivior Shares Surge After Strong Quarterly Results and Higher 2026 Outlook - Yahoo Finance
Supernus Pharmaceuticals (SUPN) details Indivior merger call and planned S-4 proxy filings - Stock Titan
Indivior Pharmaceuticals Inc. R (E7P.MU) Q2 FY2026 & Merger earnings call transcript - Yahoo Finance
CNS-focused Supernus and Indivior agree merger terms - pharmaphorum
Supernus and Indivior agree to merge in all-stock deal - Investing.com
Indivior Pharmaceuticals Inc. (INDV) Q2 Earnings and Revenues Beat Estimates - finance.yahoo.com
Weekly Recap: All-stock merger with Supernus and 2026 SUBLOCADE guidance - TradingView
Indivior stock soars 9% on strong earnings beat and raised guidance - Investing.com South Africa
Weekly Recap: Indivior merger, 1.5401 exchange and Q2 revenue, guide up - TradingView
Supernus Pharmaceuticals (SUPN) agrees merger-of-equals with Indivior and $1B special dividend - Stock Titan
Finanzdaten der Indivior Pharmaceuticals Inc-Aktie (INDV)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.41%
0.33%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):